Exelon (NASDAQ:EXC) reported quarterly earnings of $0.43 per share which met the analyst consensus estimate. This is a 52.22 percent decrease over earnings of $0.90 per share from the same period last year. The company reported quarterly sales of $4.67 billion which beat the analyst consensus estimate of $4.11 billion by 13.55 percent. This is a 51.55 percent decrease over sales of $9.63 billion the same period last year.
Novo Nordisk Ups Outlook Amid Surging Demand For Weight Loss Drug Wegovy, Ozempic
Following a surge in demand for its weight-loss drug Wegovy and diabetes medication Ozempic, Novo Nordisk has revised its full-year outlook.
